source
- Eli Lilly halts phase 2 Alzheimer's trial of mevidalen after missing internal targetsEli Lilly announced it is removing mevidalen from its pipeline, ending a phase 2 trial in symptomatic Alzheimer's disease. The decision was disclosed during the company's third-quarter earnings up…
- Setara Biosciences raises $90M Series A to advance neuroscience pipeline after Jazz's $820M Actio acquisitionJazz Pharmaceuticals completed an $820 million purchase of Actio Biosciences in September, creating a new spinout called Setara Biosciences to house the remaining drug programs. Setara has secured…